Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Panelists discuss how chronic spontaneous urticaria involves autoantibody-mediated mast cell activation and degranulation, with BTK serving as a critical signaling molecule in both mast cells and B cells that produce pathogenic autoantibodies.

Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion

Dupilumab reduced itch and disease activity in patients with uncontrolled CSU, confirming prior findings from the LIBERTY-CUPID program in a phase 3 trial.

LIBERTY-CUPID Study C Confirms Benefit of Dupilumab in Biologic-Naive CSU

The latest indication for the dual inflammatory pathway-targeting biologic expands dupilumab's clinical availability to third chronic skin disease.

Regeneron, Sanofi Receive CRL for Add-On Dupilumab sBLA for Chronic Spontaneous Urticaria

The biologic sustained responses in managing sleep interference with numerically higher responses than omalizumab.

Ligelizumab Improves Sleep and Disease Burden in CSU Patients

Investigators noted that the epidemiology and disease overlap among eosinophilic diseases are poorly understood.

Overlapping Eosinophilic Diseases Linked to Greater Disease Burden in EoE Patients

Investigators review the current understanding of the role of the BTK pathway and the potential value of pharmacological inhibition of BTK as a therapeutic strategy.

BTK-Inhibition Considered for Dermatologic Conditions 

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

Phase 3 Trial on Dupilumab for Chronic Spontaneous Urticaria Stopped

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

COVID-19 Linked to Exacerbations in Skin Diseases

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

Ligelizumab and Omalizumab Optimal Treatments for Chronic Spontaneous Urticaria 

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab. 

Ligelizumab Superior to Omalizumab for Chronic Spontaneous Urticaria Clearance

The HCPLive chronic idiopathic urticaria page is a comprehensive resource for clinical news and insights on CIU. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

Chronic Idiopathic Urticaria